Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Morphine + ropivacaine is a combination of two pharmaceutical agents used primarily for regional anesthesia and postoperative pain management. Morphine is an opioid analgesic that acts as an agonist at the mu-opioid receptor, providing potent central nervous system-mediated pain relief. Ropivacaine is an aminoamide local anesthetic that blocks voltage-gated sodium channels in nerve cells, inhibiting nerve impulse conduction and producing local or regional anesthesia. When administered together—typically via epidural or intrathecal routes—the combination provides superior analgesia compared to either drug alone, with morphine contributing prolonged opioid-mediated pain control and ropivacaine offering rapid-onset sensory blockade with minimal motor impairment. This combination has been shown to improve postoperative recovery quality after surgeries such as lower abdominal or colorectal procedures, though it may increase the incidence of side effects like pruritus and hypotension[2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on morphine + ropivacaine.